Article (Scientific journals)
Efficacy and safety of Jentadueto(R) (linagliptin plus metformin).
SCHEEN, André
2013In Expert Opinion on Drug Safety, 12 (2), p. 275-89
Peer Reviewed verified by ORBi
 

Files


Full Text
Txt Clean Revised version Jentadueto Expert Opinion Drug Safety.pdf
Author preprint (207.51 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
DPP-4 inhibitor; Type 2 diabetes mellitus; Fixed-dose combination; Linagliptin; Metformin; Pharmacokinetics
Abstract :
[en] INTRODUCTION: Metformin is the first-choice drug in the management of type 2 diabetes. However, most patients require a combined therapy to reach and/or maintain targets of glucose control. Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for combined therapy with metformin. Linagliptin shares a similar pharmacodynamic (PD) profile with other gliptins, but has a unique pharmacokinetic (PK) profile characterized by negligible renal excretion. AREAS COVERED: An extensive literature search was performed to analyze the potential PK/PD interactions between linagliptin and metformin. They are not prone to PK drug-drug interactions. The two compounds may be administered together, either separately or using a fixed-dose combination (FDC) as shown by bioequivalence studies. The addition of linagliptin in patients not well controlled with metformin alone has proven its efficacy in improving glucose levels with a good safety profile. Initial co-administration of linagliptin plus metformin improves glucose control more potently than either compound separately, without hypoglycemia, weight gain or increased metformin-related gastrointestinal side effects. EXPERT OPINION: The linagliptin plus metformin combination may offer some advantages over the classical sulfonylurea-metformin combination. Even if linagliptin is safe in patients with renal impairment, the use of metformin (and thus of the linagliptin plus metformin FDC) is still controversial in this population.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Efficacy and safety of Jentadueto(R) (linagliptin plus metformin).
Publication date :
2013
Journal title :
Expert Opinion on Drug Safety
ISSN :
1474-0338
eISSN :
1744-764X
Publisher :
Taylor & Francis, United Kingdom
Volume :
12
Issue :
2
Pages :
275-89
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 02 April 2013

Statistics


Number of views
228 (1 by ULiège)
Number of downloads
1889 (0 by ULiège)

Scopus citations®
 
9
Scopus citations®
without self-citations
4
OpenCitations
 
6

Bibliography


Similar publications



Contact ORBi